Evidence map›Paper›PMID 40331921›Full record

ArticleJournal of diabetes investigation2025

Association of the gut microbiota with type 2 diabetes: Links to disease and remission in the Japanese population.

Keita Kinoshita, Naoki Ozato, Tohru Yamaguchi, Kenta Mori, Yoshihisa Katsuragi, Noriaki Sato, Seiya Imoto, Kazushige Ihara, Koichi Murashita, Shigeyuki Nakaji and 1 more

Abstract read
In one paragraph

Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Review
  4. Recent progress of remission in type 2 diabetes.Therapeutic advances in endocrinology and metabolism · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Keita KinoshitaDepartment of Active Life Promotion Sciences, Hirosaki University Graduate School of Medicine, Aomori, Japan.ORCID https://orcid.org/0000-0001-8373-1789
Naoki OzatoDepartment of Active Life Promotion Sciences, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Tohru YamaguchiHuman Health Care Products Research Laboratories, Kao Corporation, Tokyo, Japan.
Kenta MoriDepartment of Active Life Promotion Sciences, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Yoshihisa KatsuragiDepartment of Active Life Promotion Sciences, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Noriaki SatoHuman Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Seiya ImotoHuman Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Kazushige IharaDepartment of Social Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Koichi MurashitaResearch Institute of Health Innovation, Hirosaki University, Aomori, Japan.
Shigeyuki NakajiDepartment of Social Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Tatsuya MikamiInnovation Center for Health Promotion, Hirosaki University Graduate School of Medicine, Aomori, Japan.

Funding

Center of Innovation Program JPMJCA2201Center of Innovation Program JPMJCE1302Center of Innovation Program JPMJPF2210Kao Corporation
6 · The paper itself

Abstract

backgroundAlthough the gut microbiota is associated with type 2 diabetes (T2D) and its remission in clinical settings, their relationship in the general population remains unclear. This study aimed to investigate the association between the gut microbiota and T2D and its remission in a population-based setting.

methodsA cross-sectional study was conducted on 1,639 Japanese participants with (n = 106) or without (n = 1,533) T2D. The gut microbiota was compared between the two groups using multivariable-adjusted logistic regression. The relative abundance of the gut microbiota in fecal samples was calculated using 16S ribosomal RNA amplification. The association between the gut microbiota and T2D remission was determined via longitudinal analyses.

resultsSix genera were independently associated with T2D; a higher abundance of Faecalibacterium, Blautia, Roseburia, and Oscillibacter was significantly associated with a lower odds ratio for T2D, whereas a higher abundance of Megasphaera and Lactobacillus was significantly associated with a higher odds ratio for T2D. Of these, only Blautia abundance was significantly increased in the remission group compared with that in the non-remission group. In the remission group, an increase in Blautia abundance was significantly correlated with an increase in adiponectin level and skeletal muscle mass.

conclusionsSpecific gut microbes were significantly associated with T2D and its remission. The gut microbiota may represent a potential area for further exploration in T2D treatment and prevention. However, additional large-scale cohort studies or intervention studies using a probiotic or prebiotic approach are needed to validate these findings.

Indexed as

Diabetes Mellitus, Type 2Gastrointestinal MicrobiomeAdultAgedCross-Sectional StudiesEast Asian PeopleFecesFemaleFollow-Up StudiesHumansJapanMaleMiddle AgedPrognosisRemission InductionGut microbiotaRemissionType 2 diabetes

Identifiers

PMID40331921
PMCPMC12209512

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.